Evidence map›Paper›PMID 22069581›Full record

ReviewToxins2010

Botulinum neurotoxin for pain management: insights from animal models.

Flaminia Pavone, Siro Luvisetto

Open access · goldAbstract readReview
In one paragraph

Review in Toxins, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Observational
  5. Suppression of skin lesions and SLE nephritis by increasing Treg in MRL/FASAdvances in rheumatology (London, England) · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. XeominToxins · 2023
    Article
  12. Article
  13. Review
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Flaminia PavoneCNR, Institute of Neuroscience-Roma, via del Fosso di Fiorano 64, I-00143 Roma, Italy. flaminia.pavone@cnr.it
Siro Luvisetto

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The action of botulinum neurotoxins (BoNTs) at the neuromuscular junction has been extensively investigated and knowledge gained in this field laid the foundation for the use of BoNTs in human pathologies characterized by excessive muscle contractions. Although much more is known about the action of BoNTs on the peripheral system, growing evidence has demonstrated several effects also at the central level. Pain conditions, with special regard to neuropathic and intractable pain, are some of the pathological states that have been recently treated with BoNTs with beneficial effects. The knowledge of the action and potentiality of BoNTs utilization against pain, with emphasis for its possible use in modulation and alleviation of chronic pain, still represents an outstanding challenge for experimental research. This review highlights recent findings on the effects of BoNTs in animal pain models.

Indexed as

AnimalsBotulinum ToxinsDisease Models, AnimalHumansNeurotoxinsPainPain ManagementBotulinum ToxinsNeurotoxinsanalgesiaanimal modelbotulinum toxincentral sensitizationchronic paininflammatory painpainperipheral sensitizationretrograde axonal transportSNARE

Identifiers

PMID22069581
PMCPMC3153188
OpenAlexW2111899613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.